PolyActiva $9.2m cash injection
20 February, 2013 by Tim DeanPolyActiva has raised $9.2m to further the development of its polymer drug delivery technology platform.
Patent review bonanza has industry under siege
20 February, 2013 by Dr Anna Lavelle, CEO, AusBiotechContinual government reviews of the intellectual property system are creating uncertainty in the life sciences industry that could hurt its future success.
Industry applauds Labor policy to aid innovation
19 February, 2013 by Tim DeanLabor announced yesterday its long-awaited policy on jobs and innovation, offering several reforms aimed at aiding innovative companies and biotechs.
Novogen stocks soar following successful study
18 February, 2013 by Tim DeanNovogen (ASX:NRT) stocks have soared over 200% following a study that found its experimental drug CS-6 can kill not only cancer cells but also cancer stem cells.
Movers & shakers: Alchemia appoints new CEO
18 February, 2013 by Tim DeanAlchemia has appointed former Chief Financial Officer Charles Walker to the post of Chief Executive after Peter Smith stepped down following the failed Audeo Oncology demerger.
Industry leaders’ views needed in the 2013 AusBiotech Industry Position Survey
18 February, 2013 by AusBiotechAusBiotech invites industry leaders to participate in the annual CEO Industry Position Survey 2013.
Gene patent upheld by Federal Court
18 February, 2013 by Tim DeanThe Federal Court has ruled in favour of Myriad Genetics and its patent of mutations in the BRCA1 gene, although some have expressed concern at the result.
MRCF invests $1.25m in Helmedix to develop autoimmune therapies
14 February, 2013 by Tim DeanEarly-stage biopharma Helmedix has received $1.25m of start-up funding from the Medical Research Commercialisation Fund to develop therapies targeting autoimmune diseases.
Early bird for inaugural Australia China Life Science Summit ending soon
14 February, 2013 by AusBiotechEarly bird registrations will close on 15 February for AusBiotech’s inaugural Australia China Life Science Summit.
Sirtex posts another boost in sales and profit
14 February, 2013 by Tim DeanSirtex (ASX:SRX) has seen sales of SIRSpheres increase by 30.5% and net profit increase by 27.6% to $7.8 million in its half-year results.
BioDiem could help fight biological weapons
14 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and a US army institute will collaborate on research into using antimicrobial BDM-I as a countermeasure for biological weapons including anthrax.
CSL hits new heights with 24% increase in profit
13 February, 2013 by Dylan Bushell-EmblingThe market has reacted positively to news that CSL (ASX:CSL) saw a 24% increase in net profit to US$627 million in 1H13 and has completed the restructure of its Australian operations.
Allied receives ISO certification for CardioCel
13 February, 2013 by Tim DeanAllied Healthcare (ASX:AHZ) has received ISO 13485 certification for regenerative therapy CardioCel, bringing it a step closer to European CE Mark approval.
Mesoblast boosts R&D spend on stem cell platform
12 February, 2013 by Dylan Bushell-EmblingThe expansion of Mesoblast’s MPC adult stem cell development programs came at a cost in 1H13, but the company has more than adequate cash reserves to cover the increased burn.
MicroRNA found to inhibit spread of melanoma
12 February, 2013 by Tim DeanA study has shown a microRNA being investigated by MiReven can inhibit the spread of metastatic melanoma, reinforcing its prospect as a potential anticancer agent.
